Various Cancers Are Linked to Diabetes Medication

There are a number of reports of various types of cancer associated with popular drugs prescribed to help patients control their diabetes type two. The report claims that the drug had caused pancreatic cancer, pancreatitis, thyroid cancer, and renal failure. The drug's manufacturer, based in Denmark, was given the approval to sell the drug to patients in the United States in 2010.

The diabetes drug is given as a daily injection and is referred to as a form of glucagon-like peptide (GLP-1) therapy. GLP-1 is a hormone that helps to produce insulin, which is needed to aid in the breakdown of sugars found in the body. You can get more information about pancreatic cancer online at https://positivebioscience.com/pancreatic-cancer/.

GLP-1 therapy works to mimic the function of naturally produced hormones. That being said, the current study has found that the use of GLP-1 drug therapy is produced can actually increase the potential for serious health complications including pancreatic cancer, pancreatitis, thyroid cancer, and renal failure.

CyberKnife Shows High Quality of Life

Image Source: Google

The information was released by a patient safety group, Public Citizen, found that the diabetes drug has been approved for use although three reviewers from the United States Food and Drug Administration (FDA) advised not approved. 

Director of Public Citizen's Health Research Group, and representatives for consumers who sits on the advisory panel for drug safety and risk management for the FDA, feel that drugs should be banned and that approving the drug is a major threat to the safety and health of patients with diabetes in the United States.

If you or someone who knows you take diabetes medication and you are diagnosed with pancreatic cancer, pancreatitis, thyroid cancer, or kidney failure, you should not hesitate to contact a personal injury attorney as soon as possible. Sufficient legal professionals skilled in the field of law and will evaluate your case to determine how best to proceed.